lundi 20 avril 2015

Onco Actu du 20 avril 2015

A lire aussi : l'autre billet du jour "Spécial AACR"

1. Biologie


Cancer research, H-Ras and the "easy" way [Genetics and Your Health Blog]


Protein Spurs T-Cell Proliferation [The Scientist]

3.1 Tabac


E-cigarette battle heats up [Harvard Gazette]


Study doesn't prove e-cigs make quitting smoking harder [NHS Choices]


Many teens try e-cigarettes, but few become regular users [BMJ Blogs]


Youth e-cigarette data prompts new calls to speed regulation [Reuters]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...


FDA and CMS Form Task Force on LDT Quality Requirements [FDA Voice]

4.12 Biopsies liquides


Another one of those ‘simple blood tests’ you’re always reading about [Cancer Research UK]


Blood Test Shows Promise as Alternative to Cancer Biopsy [NY Times]


4.2 Dép., diag. & prono. - Génome


Novel Genomics Technique Could Predict Cancer Therapy Outcomes [GEN]


4.9 Dép., diag. & prono. - Sein


Assessing Breast Cancer Risk: Beyond the Angelina Effect [DNA Science Blog]



Cutting Through The Hyped Costs Of Mammograms [Forbes]

5. Traitements


What you need to know about the EU Clinical Trial Regulation [Pharmafile]

5.10 Traitements - Essais


CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early [BMS]


BMS' PD-1 drug Opdivo continues on stellar trajectory [FiercePharma]


Bristol's Opdivo proves effective against second type of lung cancer [Reuters]

5.12 Immunothérapies


Cancer Immunotherapy Timeline [Cancer Research Institute]


Discovery could 'boost immune system's cancer fighting ability' [NHS Choices]

5.2 Pharma


Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer [Merck]


Roche to Skip Ahead to Late-Stage Study for Breast Cancer Drug [Bloomberg Business]


AstraZeneca reports strong progress with cancer drugs ahead of results [The Guardian]

5.2.1 Pharma - Partenariats


Innate Pharma and Sanofi Collaborate on Next Generation Antibody-Drug Conjugates Using Innate's Site-Sepecific Conjugation Technology [Innate Pharma]

5.6 ESMO


ELCC 2015 Press Release: Smokers Underestimate Risks of a Few Cigarettes [ESMO]


ELCC 2015 Press Release: One in Four Advanced Lung Cancer Patients Tested for EGFR Mutations Started on First-line Treatment Before Test Results Available [ESMO]


ELCC 2015 Press Release: DNA Blood Test Detects Lung Cancer Mutations [ESMO]


ELCC 2015 News: Detection of EGFR T790M Mutation from Circulating Tumour DNA in Urine of Patients with Metastatic NSCLC [ESMO]


New international survey of lung cancer oncologists highlights underutilization of personalized treatments [Boehringer Ingelheim]

6.1 Observation


Future Directions for NCI’s Surveillance Research Program [National Cancer Institute]

6.10 Politiques


Election 2015: what are the parties saying about cancer? [Cancer Research UK]


Doug Lowy (NCI): “We Need to Continually Look at the Distribution of Funds That We Allocate to the Areas of Investment [The Cancer Letter]

6.9 Controverses


The reproducibility of Science. A meeting report. [DC's Improbable Science]


US societies push back against NIH reproducibility guidelines [Nature News & Comment]


MD Anderson Execs Get Big Raises In the Midst of Faculty Morale Woes [The Cancer Letter]